These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 20392161)

  • 1. Anti-tuberculosis activity and drug interaction with nevirapine of inhalable lipid microspheres containing rifampicin in murine model.
    Disratthakit A; Doi N; Takenaga M; Ohta Y
    J Microencapsul; 2010; 27(4):365-71. PubMed ID: 20392161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis.
    Hirota K; Hasegawa T; Nakajima T; Inagawa H; Kohchi C; Soma G; Makino K; Terada H
    J Control Release; 2010 Mar; 142(3):339-46. PubMed ID: 19951729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of inhibitory effect of rifalazil and rifampicin against Mycobacterium ulcerans infection induced in mice].
    Nakanaga K; Saito H; Ishii N; Goto M
    Kekkaku; 2004 May; 79(5):333-9. PubMed ID: 15211873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis.
    Cohen K; van Cutsem G; Boulle A; McIlleron H; Goemaere E; Smith PJ; Maartens G
    J Antimicrob Chemother; 2008 Feb; 61(2):389-93. PubMed ID: 18096560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis.
    Ohashi K; Kabasawa T; Ozeki T; Okada H
    J Control Release; 2009 Apr; 135(1):19-24. PubMed ID: 19121349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic efficacy of benzoxazinorifamycin KRM-1648 against experimental murine tuberculosis: (1). A study on the efficacy of short course treatment with the intratracheal and intravenous infection model].
    Doi N
    Kekkaku; 1998 Feb; 73(2):53-64. PubMed ID: 9545697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin.
    Manosuthi W; Sungkanuparph S; Thakkinstian A; Rattanasiri S; Chaovavanich A; Prasithsirikul W; Likanonsakul S; Ruxrungtham K
    Clin Infect Dis; 2006 Jul; 43(2):253-5. PubMed ID: 16779754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig.
    Garcia-Contreras L; Sethuraman V; Kazantseva M; Godfrey V; Hickey AJ
    J Antimicrob Chemother; 2006 Nov; 58(5):980-6. PubMed ID: 16971416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nevirapine plasma concentrations and concomitant use of rifampin in patients coinfected with HIV-1 and tuberculosis.
    Autar RS; Wit FW; Sankote J; Mahanontharit A; Anekthananon T; Mootsikapun P; Sujaikaew K; Cooper DA; Lange JM; Phanuphak P; Ruxrungtham K; Burger DM
    Antivir Ther; 2005; 10(8):937-43. PubMed ID: 16430199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid microsphere formulation containing rifampicin targets alveolar macrophages.
    Takenaga M; Ohta Y; Tokura Y; Hamaguchi A; Igarashi R; Disratthakit A; Doi N
    Drug Deliv; 2008; 15(3):169-75. PubMed ID: 18379929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.
    Manosuthi W; Ruxrungtham K; Likanonsakul S; Prasithsirikul W; Inthong Y; Phoorisri T; Sungkanuparph S
    Clin Infect Dis; 2007 Jan; 44(1):141-4. PubMed ID: 17143831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid.
    Quenelle DC; Winchester GA; Staas JK; Barrow EL; Barrow WW
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1637-44. PubMed ID: 11353605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Studies on therapeutic efficacy of a new anti-tuberculous drug, benzoxazinorifamycin, against murine experimental mycobacterial infections: attempt at various regimens and protocols].
    Tomioka H; Saito H
    Kekkaku; 1994 Nov; 69(11):703-10. PubMed ID: 7837724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A study on drug regimens against Mycobacterium avium-intracellulare infection (3). The therapeutic effect of some antimicrobial agents to murine infection model].
    Sakurai N
    Kekkaku; 1988 Jun; 63(6):447-60. PubMed ID: 3172623
    [No Abstract]   [Full Text] [Related]  

  • 16. Do we still need lead-in dosing of nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy?
    Chang SY; Lin SW; Hung CC
    Clin Infect Dis; 2009 Nov; 49(9):1452-3; author reply 1453-4. PubMed ID: 19824849
    [No Abstract]   [Full Text] [Related]  

  • 17. [In vitro antimycobacterial activity of clarithromycin and its therapeutic efficacy against Mycobacterium intracellulare infection induced in mice].
    Tomioka H; Sato K; Saito H
    Kekkaku; 1993 Apr; 68(4):293-9. PubMed ID: 8497119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.
    Pandey R; Khuller GK
    J Antimicrob Chemother; 2004 Jul; 54(1):266-8. PubMed ID: 15128731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Experience of tacrolimus-based immunosuppression in living-related liver transplantation complicated with graft tuberculosis: interaction with rifampicin and side effects.
    Kiuchi T; Tanaka K; Inomata Y; Uemoto S; Satomura K; Egawa H; Uyama S; Sano K; Okajima H; Yamaoka Y
    Transplant Proc; 1996 Dec; 28(6):3171-2. PubMed ID: 8962229
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.